IL302873A - Macrocycles Containing a 1,3,4-OXADIAZOLE Ring for Use as Cystic Fibrosis Conductance Modulators - Google Patents
Macrocycles Containing a 1,3,4-OXADIAZOLE Ring for Use as Cystic Fibrosis Conductance ModulatorsInfo
- Publication number
- IL302873A IL302873A IL302873A IL30287323A IL302873A IL 302873 A IL302873 A IL 302873A IL 302873 A IL302873 A IL 302873A IL 30287323 A IL30287323 A IL 30287323A IL 302873 A IL302873 A IL 302873A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- therapeutic agent
- additional therapeutic
- independently selected
- optionally substituted
- Prior art date
Links
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical group C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 title 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 57
- 239000003814 drug Substances 0.000 claims 54
- 150000003839 salts Chemical class 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 238000000034 method Methods 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 150000002367 halogens Chemical class 0.000 claims 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 22
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 125000004429 atom Chemical group 0.000 claims 9
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 6
- HBZAZSCNDMDWEU-WREZULKGSA-N 3,5-diamino-6-chloro-n-[n'-[4-[4-[2-[hexyl-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]amino]ethoxy]phenyl]butyl]carbamimidoyl]pyrazine-2-carboxamide Chemical compound C1=CC(OCCN(CCCCCC)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CC=C1CCCCNC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N HBZAZSCNDMDWEU-WREZULKGSA-N 0.000 claims 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- WOXOLLSAICIZNO-UHFFFAOYSA-N [5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)CO WOXOLLSAICIZNO-UHFFFAOYSA-N 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- -1 and Q) Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 3
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- YFEYDNAKCSOOOG-YCXOGWGTSA-N (2S,3R,4S,5S)-3-tert-butyl-4-[[2-methoxy-5-(trifluoromethyl)pyridin-3-yl]methoxy]-5-(2-methylphenyl)-1-[(2S)-oxane-2-carbonyl]pyrrolidine-2-carboxylic acid Chemical compound C(C)(C)(C)[C@@H]1[C@H](N([C@H]([C@H]1OCC=1C(=NC=C(C=1)C(F)(F)F)OC)C1=C(C=CC=C1)C)C(=O)[C@H]1OCCCC1)C(=O)O YFEYDNAKCSOOOG-YCXOGWGTSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- XRPSUWYWZUQALB-UHFFFAOYSA-N 2-[7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2-yl]-n-methyl-n-(2-methyl-1,3-benzoxazol-6-yl)acetamide Chemical compound N=1N(CC(=O)N(C)C=2C=C3OC(C)=NC3=CC=2)C(=O)C2=CC(OCC)=CC=C2C=1C1=CC=CC(F)=C1 XRPSUWYWZUQALB-UHFFFAOYSA-N 0.000 claims 2
- ZYOATBKPEFZNGP-UHFFFAOYSA-N 3,5-diamino-6-chloro-n-[n'-[4-[4-(2,3-dihydroxypropoxy)phenyl]butyl]carbamimidoyl]pyrazine-2-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.N1=C(Cl)C(N)=NC(N)=C1C(=O)NC(=N)NCCCCC1=CC=C(OCC(O)CO)C=C1 ZYOATBKPEFZNGP-UHFFFAOYSA-N 0.000 claims 2
- USHQRIKZLHNPQR-SNVBAGLBSA-N 3-amino-6-methoxy-n-[(2r)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide Chemical compound COC1=NC(C(=O)NC[C@@](C)(O)C(F)(F)F)=C(N)C=C1C(F)(F)F USHQRIKZLHNPQR-SNVBAGLBSA-N 0.000 claims 2
- 102000003787 Anoctamin-1 Human genes 0.000 claims 2
- 108090000160 Anoctamin-1 Proteins 0.000 claims 2
- GHTGYZMBQPXTCQ-UHFFFAOYSA-N CC1(C)Cc2c(sc(NC(=O)c3ccn[nH]3)c2C(N)=O)C(C)(C)O1 Chemical compound CC1(C)Cc2c(sc(NC(=O)c3ccn[nH]3)c2C(N)=O)C(C)(C)O1 GHTGYZMBQPXTCQ-UHFFFAOYSA-N 0.000 claims 2
- 229940126052 ENaC inhibitor Drugs 0.000 claims 2
- 229940123084 GPR39 agonist Drugs 0.000 claims 2
- TYQIFWXBQYAKCR-UHFFFAOYSA-N N-[5-hydroxy-2,4-bis(trimethylsilyl)phenyl]-4-oxo-1H-quinoline-3-carboxamide Chemical compound C[Si](C)(C)C1=CC(=C(NC(=O)C2=CNC3=C(C=CC=C3)C2=O)C=C1O)[Si](C)(C)C TYQIFWXBQYAKCR-UHFFFAOYSA-N 0.000 claims 2
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- XPEHHUISIBFLHX-RAIGVLPGSA-N O[C@H](C)C1=NN=C(O1)[C@@H]1C[C@H](C1)NC(=O)C1=CC(=NO1)C1=CC=CC=C1 Chemical compound O[C@H](C)C1=NN=C(O1)[C@@H]1C[C@H](C1)NC(=O)C1=CC(=NO1)C1=CC=CC=C1 XPEHHUISIBFLHX-RAIGVLPGSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 2
- 229960002576 amiloride Drugs 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 2
- 229940070817 icenticaftor Drugs 0.000 claims 2
- 229940015640 navocaftor Drugs 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- XUXATUPUQBOACO-GFCCVEGCSA-N 1-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound O[C@H](CN1C(=CC2=CC(=C(C=C12)F)C1(CC1)C(=O)N)C(CO)(C)C)CO XUXATUPUQBOACO-GFCCVEGCSA-N 0.000 claims 1
- UMOGNCVNHXWFIX-VIFPVBQESA-N 3-amino-N-[(2S)-2-hydroxypropyl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridine-2-carboxamide Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C(=O)NC[C@H](C)O UMOGNCVNHXWFIX-VIFPVBQESA-N 0.000 claims 1
- 101100063435 Caenorhabditis elegans din-1 gene Proteins 0.000 claims 1
- 229940126130 GLPG2451 Drugs 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 229920000180 alkyd Polymers 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- QVDYQHXNAQHIKH-TZIWHRDSSA-N galicaftor Chemical compound FC1(OC2=C(O1)C=CC(=C2)C1(CC1)C(=O)N[C@@H]1C[C@@H](OC2=CC(=CC=C12)OC(F)F)C1=CC=C(C(=O)O)C=C1)F QVDYQHXNAQHIKH-TZIWHRDSSA-N 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063115552P | 2020-11-18 | 2020-11-18 | |
PCT/US2021/072475 WO2022109573A1 (en) | 2020-11-18 | 2021-11-17 | Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of cystic fibrosis transmembrane conductance regulator |
Publications (1)
Publication Number | Publication Date |
---|---|
IL302873A true IL302873A (en) | 2023-07-01 |
Family
ID=79602287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL302873A IL302873A (en) | 2020-11-18 | 2021-11-17 | Macrocycles Containing a 1,3,4-OXADIAZOLE Ring for Use as Cystic Fibrosis Conductance Modulators |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP4247817A1 (zh) |
JP (1) | JP2023549547A (zh) |
KR (1) | KR20230123522A (zh) |
CN (1) | CN116670140A (zh) |
AR (1) | AR124090A1 (zh) |
AU (1) | AU2021383176A1 (zh) |
CA (1) | CA3201793A1 (zh) |
CL (1) | CL2023001398A1 (zh) |
CO (1) | CO2023007896A2 (zh) |
CR (1) | CR20230260A (zh) |
DO (1) | DOP2023000099A (zh) |
EC (1) | ECSP23045439A (zh) |
IL (1) | IL302873A (zh) |
MX (1) | MX2023005721A (zh) |
PE (1) | PE20231380A1 (zh) |
WO (1) | WO2022109573A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202333699A (zh) * | 2022-02-03 | 2023-09-01 | 美商維泰克斯製藥公司 | 囊腫纖維化之治療方法 |
WO2023154291A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
WO2023224931A1 (en) * | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2024054851A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions and methods of using thereof |
WO2024056779A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide |
WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
WO2024056791A1 (en) * | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5886433B2 (ja) * | 2011-09-16 | 2016-03-16 | ノバルティス アーゲー | 嚢胞性線維症処置のためのヘテロ環式化合物 |
MX2020008268A (es) * | 2018-02-15 | 2020-09-21 | Vertex Pharma | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos. |
-
2021
- 2021-11-17 EP EP21843853.9A patent/EP4247817A1/en active Pending
- 2021-11-17 JP JP2023529022A patent/JP2023549547A/ja active Pending
- 2021-11-17 CR CR20230260A patent/CR20230260A/es unknown
- 2021-11-17 CA CA3201793A patent/CA3201793A1/en active Pending
- 2021-11-17 KR KR1020237020002A patent/KR20230123522A/ko unknown
- 2021-11-17 AU AU2021383176A patent/AU2021383176A1/en active Pending
- 2021-11-17 MX MX2023005721A patent/MX2023005721A/es unknown
- 2021-11-17 PE PE2023001653A patent/PE20231380A1/es unknown
- 2021-11-17 WO PCT/US2021/072475 patent/WO2022109573A1/en active Application Filing
- 2021-11-17 CN CN202180090910.1A patent/CN116670140A/zh active Pending
- 2021-11-17 IL IL302873A patent/IL302873A/en unknown
- 2021-11-18 AR ARP210103184A patent/AR124090A1/es unknown
-
2023
- 2023-05-16 CL CL2023001398A patent/CL2023001398A1/es unknown
- 2023-05-17 DO DO2023000099A patent/DOP2023000099A/es unknown
- 2023-06-16 CO CONC2023/0007896A patent/CO2023007896A2/es unknown
- 2023-06-16 EC ECSENADI202345439A patent/ECSP23045439A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20231380A1 (es) | 2023-09-07 |
CL2023001398A1 (es) | 2023-11-24 |
KR20230123522A (ko) | 2023-08-23 |
AR124090A1 (es) | 2023-02-15 |
MX2023005721A (es) | 2023-07-25 |
AU2021383176A1 (en) | 2023-06-22 |
CA3201793A1 (en) | 2022-05-27 |
JP2023549547A (ja) | 2023-11-27 |
CN116670140A (zh) | 2023-08-29 |
ECSP23045439A (es) | 2023-08-31 |
WO2022109573A1 (en) | 2022-05-27 |
EP4247817A1 (en) | 2023-09-27 |
CR20230260A (es) | 2023-10-05 |
CO2023007896A2 (es) | 2023-09-18 |
DOP2023000099A (es) | 2023-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL302873A (en) | Macrocycles Containing a 1,3,4-OXADIAZOLE Ring for Use as Cystic Fibrosis Conductance Modulators | |
RU2012125763A (ru) | Спироиндолинонпирролидины | |
RU2701156C9 (ru) | Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах | |
AU2008228186C1 (en) | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | |
KR20070120531A (ko) | 벤즈이미다졸 화합물 | |
TWI812496B (zh) | 三環性螺化合物之用途 | |
US11319303B2 (en) | Compound used as autophagy regulator, and preparation method therefor and uses thereof | |
JP2014506599A5 (zh) | ||
SI3022192T1 (en) | Piperidinyl indole derivatives and their use as inhibitors of complementary factor B | |
JP2019518041A5 (zh) | ||
JP2015500275A5 (zh) | ||
CN111153899A (zh) | 一种取代吡啶化合物、其制备方法和用途 | |
WO2012003405A1 (en) | Sgc stimulators | |
JP2016505536A5 (zh) | ||
CA2737894A1 (en) | Pyrazolo pyridine derivatives as nadph oxidase inhibitors | |
CA3093138C (en) | Heteroaryl compounds as kinase inhibitor | |
RU2014121390A (ru) | Новые дизамещенные соединения 3,4-диамино-3-циклобутен-1,2-диона для использования при лечении опосредованных цитокинами заболеваний | |
US20170015669A1 (en) | Heteroarylamide inhibitors of tbk1 | |
ZA200100913B (en) | New compounds. | |
IL291958A (en) | History of 4,2,1-oxadiazole as liver x receptor agonists | |
JP2013536233A5 (zh) | ||
AU2013328609B2 (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses | |
JP2015500277A (ja) | アンドロゲン受容体拮抗薬としての環状尿素誘導体 | |
TWI439270B (zh) | 苯并咪唑化合物 | |
AU2018228114B2 (en) | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND |